News & Press Releases
Latest News and Press Releases
New Insights into the Role of Enteroviruses in Type 1 Diabetes
In type 1 diabetes (T1D), the insulin-producing beta cells of the pancreas are destroyed, leading to a lifelong need for insulin treatment. Recent research has…
Vactech Appoints Dr. Tero Välimaa as New Chief Executive Officer
Experienced Leader Brings Over 25 Years of Pharmaceutical and Medical Device Expertise to Vactech Tampere, Finland, October 19, 2023 — Vactech Ltd., a leading biotechnology company…
The results of the PRV-101 vaccine Phase I trial published in Diabetologia.
Safety, tolerability and immunogenicity of PRV-101, a multivalent vaccine targeting coxsackie B viruses (CVBs) associated with type 1 diabetes: a double-blind randomised placebo-controlled Phase I…
Vactech announces positive final results from First-In-Human study of Coxsackievirus B Vaccine Candidate PRV-101
PRV-101 continued to be well tolerated and elicited durable high titers of virus-neutralizing antibodies in a dose-dependent fashion in healthy volunteers Tampere, Finland – Vactech…
Vactech announces positive final results from First-In-Human study of Coxsackievirus B Vaccine Candidate PRV-101
PRV-101 was well tolerated and elicited high titers of virus-neutralizing antibodies in a dose-dependent fashion in healthy volunteers Positive results support further development activities Tampere,…
Vactech announces positive interim results from First-in-Human Study of Coxsackievirus B Vaccine Candidate PRV-101 against Type 1 Diabetes
PRV-101 was well tolerated and elicited high titers of virus-neutralizing antibodies in a dose-dependent fashion in healthy volunteers Positive results support further development activities Tampere,…
Vactech announces that the First-in-Human Study of Coxsackievirus B Vaccine Candidate PRV-101 has been initiated
Potential to be the first vaccine for the prevention of coxsackievirus B, a presumed infectious trigger in the development of Type 1 Diabetes (T1D) and…
Vactech and Provention Bio announce publication of proof-of-concept data for a preclinical prototype of coxsackievirus B vaccine
Provention Bio and Vactech Announce Publication of Proof-of-Concept Data for a Preclinical Prototype of Coxsackievirus B Vaccine -- The preclinical prototype vaccine is well-tolerated and…
Vactech announces issuance of US patent for Multi-CBV vaccine for preventing or treating Type 1 Diabetes
Tampere, Finland – Vactech Oy (Vactech), a biotechnology company focused on development of vaccines for Type 1 Diabetes and other immune mediated diseases, today announced…
A Coxsackievirus B vaccine protects against virus-induced diabetes in an experimental mouse model of Type 1 Diabetes
Tampere, Finland – Vactech Oy (Vactech), a biotechnology company focused on development of vaccines for Type 1 Diabetes and other immune mediated diseases, today announced…
Vactech announces a US-based strategic partnership and clinical development program focused on intercepting and preventing the onset of Type 1 Diabetes
Lead asset out-licensed to Provention Bio, Inc. for the development of a vaccine preventing Type 1 Diabetes by targeting coxsackievirus B infections Tampere, Finland –…
Vactech announces issuance of EPO patent for Multi-CBV vaccine for preventing or treating Type 1 Diabetes
Tampere, Finland – Vactech Oy (Vactech), a biotechnology company focused on development of vaccines for Type 1 Diabetes and other immune mediated diseases, today announced…
Vactech announces issuance of EPO patent for Prevention of Allergic Sensitization
Tampere, Finland – Vactech Oy (Vactech), a biotechnology company focused on development of vaccines for Type 1 Diabetes and other immune mediated diseases, today announced…
Vactech announces issuance of EPO patent for Diagnostic Assay for Type 1 Diabetes
Tampere, Finland – Vactech Oy (Vactech), a biotechnology company focused on development of vaccines for Type 1 Diabetes and other immune mediated diseases, today announced…
Vactech announces issuance of EPO patent for Use of Enterovirus for Diagnostics, Treatment and Prevention on Celiac Disease
Tampere, Finland – Vactech Oy (Vactech), a biotechnology company focused on development of vaccines for Type 1 Diabetes and other immune mediated diseases, today announced…
Enteroviral infections detected in the pancreases of living patients newly diagnosed with Type 1 Diabetes
Tampere, Finland – Vactech Oy (Vactech), a biotechnology company focused on development of vaccines for Type 1 Diabetes and other immune mediated diseases, today announced…
A new vaccine against Coxsackievirus B1 shows good efficacy and reveals no risk for accelerated diabetes development in mouse models
Tampere, Finland – Vactech Oy (Vactech), a biotechnology company focused on development of vaccines for Type 1 Diabetes and other immune mediated diseases, today announced…
Vactech announces issuance of Canadian patent for Prevention of Type 1 Diabetes and other non-Polio Enterovirus Diseases
Tampere, Finland – Vactech Oy (Vactech), a biotechnology company focused on development of vaccines for Type 1 Diabetes and other immune mediated diseases, today announced…
Risk association between coxsackieviruses and Type 1 Diabetes confirmed in Different European Populations
Tampere, Finland – Vactech Oy (Vactech), a biotechnology company focused on development of vaccines for Type 1 Diabetes and other immune mediated diseases, today announced…
Research results indicates risk association between coxsackieviruses and Type 1 Diabetes
Tampere, Finland – Vactech Oy (Vactech), a biotechnology company focused on development of vaccines for Type 1 Diabetes and other immune mediated diseases, today announced…
Vactech announces issuance of US patent for Prevention of Allergic Sensitization
Tampere, Finland – Vactech Oy (Vactech), a biotechnology company focused on development of vaccines for Type 1 Diabetes and other immune mediated diseases, today announced…
Vactech announces issuance of a completing US patent for Prevention of Type 1 Diabetes and other non-Polio Enterovirus Diseases
Tampere, Finland – Vactech Oy (Vactech), a biotechnology company focused on development of vaccines for Type 1 Diabetes and other immune mediated diseases, today announced…
Vactech announces issuance of US patent for Prevention of Type 1 Diabetes and other non-Polio Enterovirus Diseases
Tampere, Finland – Vactech Oy (Vactech), a biotechnology company focused on development of vaccines for Type 1 Diabetes and other immune mediated diseases, today announced…